Amgen and Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab - BioSpace
Amgen and Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab BioSpace
THOUSAND OAKS, Calif. /PRNewswire/ --Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ ...
Comments
Post a Comment